| Symbol | HRTX |
|---|---|
| Name | HERON THERAPEUTICS, INC. /DE/ |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA 92121 |
| Telephone | 8582514400 |
| Fax | — |
| — | |
| Website | https://www.herontx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000818033 |
| Description | Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The companys product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011. Additional info from NASDAQ: |
Hensley Mark Earl 🟡 adjusted position in 8.9K shares (1 derivative) of HERON THERAPEUTICS, INC. /DE/ (HRTX) at $0.50 Transaction Date: Aug 06, 2026 | Filing ID: 341528
Read more(10% Negative) HERON THERAPEUTICS, INC. /DE/ (HRTX) Reports Q3 2026 Financial Results
Read moreHeron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
Read moreCollard Craig A 🟡 adjusted position in 0 shares (1 derivative) of HERON THERAPEUTICS, INC. /DE/ (HRTX) Transaction Date: Jul 19, 2026 | Filing ID: 308958
Read moreForbes William P 🟡 adjusted position in 1.1K shares (1 derivative) of HERON THERAPEUTICS, INC. /DE/ (HRTX) at $0.47 Transaction Date: Jul 19, 2026 | Filing ID: 308922
Read moreDuarte Ira 🟡 adjusted position in 1.1K shares (1 derivative) of HERON THERAPEUTICS, INC. /DE/ (HRTX) at $0.47 Transaction Date: Jul 19, 2026 | Filing ID: 308887
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read more